Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNEUROPHARMACOLOGY

Pharmacological Effects of the Metabotropic Glutamate Receptor 1 Antagonist Compared with Those of the Metabotropic Glutamate Receptor 5 Antagonist and Metabotropic Glutamate Receptor 2/3 Agonist in Rodents: Detailed Investigations with a Selective Allosteric Metabotropic Glutamate Receptor 1 Antagonist, FTIDC [4-[1-(2-Fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide]

Akio Satow, Shunsuke Maehara, Satoko Ise, Hirohiko Hikichi, Miyuki Fukushima, Gentaroh Suzuki, Toshifumi Kimura, Takeshi Tanaka, Satoru Ito, Hiroshi Kawamoto and Hisashi Ohta
Journal of Pharmacology and Experimental Therapeutics August 2008, 326 (2) 577-586; DOI: https://doi.org/10.1124/jpet.108.138107
Akio Satow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shunsuke Maehara
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Satoko Ise
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hirohiko Hikichi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miyuki Fukushima
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gentaroh Suzuki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toshifumi Kimura
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takeshi Tanaka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Satoru Ito
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroshi Kawamoto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hisashi Ohta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Information

vol. 326 no. 2 577-586
DOI 
https://doi.org/10.1124/jpet.108.138107
PubMed 
18487514

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0022-3565
Online ISSN 
1521-0103
History 
  • Received February 18, 2008
  • Accepted May 16, 2008
  • Published online July 18, 2008.

Article Versions

  • Earlier version (May 16, 2008 - 11:57).
  • Earlier version (May 22, 2008 - 05:03).
  • You are viewing the most recent version of this article.
Copyright & Usage 
The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Akio Satow,
  2. Shunsuke Maehara,
  3. Satoko Ise,
  4. Hirohiko Hikichi,
  5. Miyuki Fukushima,
  6. Gentaroh Suzuki,
  7. Toshifumi Kimura,
  8. Takeshi Tanaka,
  9. Satoru Ito,
  10. Hiroshi Kawamoto and
  11. Hisashi Ohta
  1. Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., Tsukuba, Japan
  1. Address correspondence to:
    Akio Satow, Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba, Ibaraki 300-2611, Japan. E-mail: akio_sato{at}merck.com
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: May 2008 to March 2023

AbstractFullPdf
May 2008720139
Jun 200824090
Jul 20089039111
Aug 2008862676
Sep 2008483948
Oct 2008564047
Nov 2008522531
Dec 200892115
Jan 2009185240
Feb 2009112117
Mar 2009331518
Apr 2009171615
May 2009112721
Jun 2009182422
Jul 2009142618
Aug 2009112021
Sep 2009152928
Oct 2009242531
Nov 2009142430
Dec 2009221523
Jan 2010371920
Feb 2010401016
Mar 2010291824
Apr 2010232417
May 2010282123
Jun 2010382017
Jul 2010181822
Aug 2010151111
Sep 2010172216
Oct 2010302121
Nov 2010192017
Dec 2010142116
Jan 2011262624
Feb 2011241616
Mar 2011133828
Apr 2011192022
May 2011131822
Jun 2011242026
Jul 2011261936
Aug 2011221428
Sep 2011131930
Oct 2011182126
Nov 2011212939
Dec 2011172125
Jan 2012262927
Feb 2012261925
Mar 2012142328
Apr 2012262427
May 2012181632
Jun 2012151621
Jul 2012122020
Aug 2012151129
Sep 2012211733
Oct 2012172539
Nov 2012182338
Dec 2012171930
Jan 2013242521
Feb 2013171119
Mar 2013153030
Apr 2013211528
May 2013252046
Jun 2013181921
Jul 2013301021
Aug 20137816
Sep 2013431312
Oct 201316198
Nov 2013131312
Dec 2013103611
Jan 201415269
Feb 20147335
Mar 201420259
Apr 2014241411
May 201411257
Jun 201491211
Jul 2014202210
Aug 20141097
Sep 201491516
Oct 20149118
Nov 2014879
Dec 2014642
Jan 20151437
Feb 2015887
Mar 201510107
Apr 20156102
May 20151297
Jun 201591113
Jul 20155716
Aug 201518143
Sep 201516108
Oct 20151587
Nov 201513147
Dec 2015863
Jan 2016161216
Feb 2016746
Mar 201628829
Apr 20162997
May 2016171415
Jun 2016162014
Jul 2016141213
Aug 2016161326
Sep 20168149
Oct 201612021
Nov 201642011
Dec 201622418
Jan 201702910
Feb 20170237
Mar 20172367
Apr 20170196
May 201702023
Jun 20171246
Jul 201721716
Aug 201732326
Sep 201722123
Oct 201722612
Nov 201752810
Dec 201732814
Jan 20181154
Feb 201842116
Mar 201822315
Apr 201813123
May 201821921
Jun 201843925
Jul 201812424
Aug 201823317
Sep 201801718
Oct 201802323
Nov 201811314
Dec 20183535
Jan 20191615
Feb 20191414
Mar 201921210
Apr 20191433
May 20193145
Jun 201911510
Jul 20191513
Aug 20191856
Sep 20191001
Oct 20191932
Nov 20192753
Dec 20191823
Jan 20202005
Feb 20203227
Mar 20201367
Apr 2020734
May 2020801
Jun 20201533
Jul 20201611
Aug 20201223
Sep 20201235
Oct 2020646
Nov 20201322
Dec 20202838
Jan 2021291427
Feb 20211158
Mar 202146914
Apr 20211434
May 202139614
Jun 20211433
Jul 20211826
Aug 20212764
Sep 20211533
Oct 20211024
Nov 20212423
Dec 202127710
Jan 202229237
Feb 202213510
Mar 20221534
Apr 202229117
May 20221298
Jun 20224021
Jul 20222827
Aug 2022761714
Sep 2022281016
Oct 20221183
Nov 20221448
Dec 20221629
Jan 20232195
Feb 20231726
Mar 20231722

PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 326 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 326, Issue 2
1 Aug 2008
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacological Effects of the Metabotropic Glutamate Receptor 1 Antagonist Compared with Those of the Metabotropic Glutamate Receptor 5 Antagonist and Metabotropic Glutamate Receptor 2/3 Agonist in Rodents: Detailed Investigations with a Selective Allos…
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNEUROPHARMACOLOGY

Pharmacological Effects of the Metabotropic Glutamate Receptor 1 Antagonist Compared with Those of the Metabotropic Glutamate Receptor 5 Antagonist and Metabotropic Glutamate Receptor 2/3 Agonist in Rodents: Detailed Investigations with a Selective Allosteric Metabotropic Glutamate Receptor 1 Antagonist, FTIDC [4-[1-(2-Fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide]

Akio Satow, Shunsuke Maehara, Satoko Ise, Hirohiko Hikichi, Miyuki Fukushima, Gentaroh Suzuki, Toshifumi Kimura, Takeshi Tanaka, Satoru Ito, Hiroshi Kawamoto and Hisashi Ohta
Journal of Pharmacology and Experimental Therapeutics August 1, 2008, 326 (2) 577-586; DOI: https://doi.org/10.1124/jpet.108.138107

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleNEUROPHARMACOLOGY

Pharmacological Effects of the Metabotropic Glutamate Receptor 1 Antagonist Compared with Those of the Metabotropic Glutamate Receptor 5 Antagonist and Metabotropic Glutamate Receptor 2/3 Agonist in Rodents: Detailed Investigations with a Selective Allosteric Metabotropic Glutamate Receptor 1 Antagonist, FTIDC [4-[1-(2-Fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide]

Akio Satow, Shunsuke Maehara, Satoko Ise, Hirohiko Hikichi, Miyuki Fukushima, Gentaroh Suzuki, Toshifumi Kimura, Takeshi Tanaka, Satoru Ito, Hiroshi Kawamoto and Hisashi Ohta
Journal of Pharmacology and Experimental Therapeutics August 1, 2008, 326 (2) 577-586; DOI: https://doi.org/10.1124/jpet.108.138107
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • KRM-II-81 Analogs
  • Substituted Tryptamine Activity at 5-HT Receptors and SERT
  • VTA muscarinic M5 receptors and effort-choice behavior
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics